AASLD-IDDF- HKASLD Joint Symposium – Hot Topics in Chronic Hepatitis B
Welcome remarks and introduction
Debate: Patients who are on antiviral therapy for chronic hepatitis B and have low HCC risk scores can stop HCC screening
Does peginterferon have a role in HBV cure programs?
Will new HBV biomarkers help us select agents to cure HBV?
** Programme is subject to change without prior notice